RxDoctor Payments Data

Francisco Ordaz-Chavez, MD

Adult Medicine · Brawley, CANPI 1881171148

Payments from drug & device makers

$545in general payments, 2019–2025

Across 22 payments — averaging $24.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$184
  • Agios Pharmaceuticals, Inc.$85
  • Novo Nordisk$71
  • GSK$66
  • AstraZeneca$26
  • Hologic Sales And Service, LLC$22
  • plus $91 from 5 others

What the payments were for

  • Food & beverage$46084%
  • Education$8516%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$545 in reported general payments places this provider in the 65th percentile of 221 adult medicine providers in California.

See all adult medicine providers in California

Medicare billing

Part B allowed, 2024
$15,928
Medicare patients
315
Services billed
892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate130$110,829
JardianceEmpagliflozin103$100,453
TradjentaLinagliptin100$76,509
OzempicSemaglutide74$75,069
RybelsusSemaglutide30$62,387
FarxigaDapagliflozin Propanediol85$60,797
EliquisApixaban40$28,975
TrulicityDulaglutide25$22,683
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog57$20,299
EntrestoSacubitril/Valsartan16$19,007
LinzessLinaclotide24$18,013
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$12,756
XareltoRivaroxaban15$12,458
VascepaIcosapent Ethyl27$9,466
SynjardyEmpagliflozin/Metformin Hcl13$9,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$71$137,456104 claims
AstraZenecaFarxiga, Breztri Aerosphere$26$73,553106 claims
Lilly USA, LLCTrulicity$17$22,68325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 221 adult medicine providers in California.

Other adult medicine in Brawley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →